BioStock: Chordate Medical receives patent approval in the US

Chordate Medical will be granted a fourth patent in the US for the migraine treatment Ozilia. In parallel, work is underway to obtain market approval from the FDA. BioStock reached out to CEO Anders Weilandt to learn more about the opportunities in the US market.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/05/chordate-medical-receives-patent-approval-in-the-us/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se